BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing, and commercializing cancer medicines with a particular strength in hematology. The company was founded in 2010 and has grown into a fully integrated organization with operations across the U.S., China, the UK, Switzerland, and Australia. Its core commercial franchise is BRUKINSA, a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell malignancies, and it is building a broader pipeline around next-generation hematology assets such as sonrotoclax and BTK-CDAC. BeOne also collaborates with partners such as Amgen and uses a mix of internal development, external manufacturing, and third-party distribution to reach patients globally. The business is shaped by the economics of oncology R&D, where speed, clinical execution, manufacturing scale, and regulatory approvals determine whether innovation becomes durable commercial revenue.
11,0 %
87,5 %
5,4 %
+40,2 %
3.41
3.08
| % | |
|---|---|
| Commercial oncology medicines | 85% Approved cancer therapies sold in regulated markets, including BRUKINSA, tislelizumab, and pamiparib. |
| Pipeline and clinical-stage assets | 0% Preclinical and clinical oncology candidates such as sonrotoclax and BTK-CDAC that support future growth. |
| Collaboration and royalty income | 15% Revenue and monetization from strategic partnerships, including Amgen-related arrangements and royalty transactions. |
BeOne sells primarily to healthcare systems, hospitals, oncology clinics, and medical institutions that prescribe and...
Buy and administer BeOne's approved cancer medicines for patients with hematologic and solid tumors.
Procure through distributors and tender processes, making access, pricing, and compliance critical.
Influence prescribing of BRUKINSA and other oncology therapies based on clinical profile and evidence.
Buy or share rights to assets through royalty, development, and commercialization agreements.
BeOne is organized as a Swiss holding company, but its operating footprint is global and centered on the U.S...
BeOne's strategy is to convert deep oncology R&D into a durable commercial franchise by building best-in-class assets...
The company sees chronic lymphocytic leukemia and related B-cell malignancies as a foundational therapeutic area with multiple mechanisms of action.
BeOne is trying to outperform the traditional CRO-heavy model by using its own global development organization and integrated capabilities.
Commercial growth depends on reliable supply of biologics and small molecules across multiple jurisdictions.
The company uses collaborations and royalty transactions to fund growth while retaining strategic rights to key assets.
BeOne faces the classic risks of an oncology developer and commercializer: clinical failure, regulatory delay, and...
The company depends on advancing oncology candidates through trials and approvals, and failures would reduce future growth options.
Large global biopharma and regional players compete in the same oncology indications, which can limit market share and pricing power.
Sales in China rely on third-party distributors and public-hospital access under the Two-Invoice System.
The company uses a mix of internal and external manufacturing, so shortages or quality issues could interrupt supply.
Oncology medicines face payer scrutiny and policy pressure, including U.S. pricing reform and local hospital procurement constraints.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
ONCO · Pharmaceutical Preparations
Pharmaceutical Preparations
Day One Biopharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on targeted therapies for childhood and adult cancers.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
ABEO · Pharmaceutical Preparations
IMCR · Biological Products, (No Diagnostic Substances)
Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to…
: 11/08/2026